PhaseBio Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PhaseBio Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7579
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PhaseBio Pharmaceuticals Inc (PhaseBio) is a clinical-stage biopharmaceutical company that develops biotherapeutics for the treatment of orphan diseases and cardiopulmonary indications. The company offers ELP biopolymer technology, which includes PE0139 and PB1023 pipeline products. PhaseBio’s products PE0139, is a long-acting basal insulin for the treatment of hyperglycemia associated with diabetes dosed as a once-weekly injection and PB1023 is a recombinant GLP-1 analogue genetically fused to ELP biopolymer that is designed as a once-weekly treatment for hyperglycemia associated with type 2 diabetes. The company develops drugs for the treatment of endocrine, metabolic and cardiovascular disease. PhaseBio is headquartered in Malvern, Pennsylvania, the US.

PhaseBio Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 11
PhaseBio Pharma Raises USD6.6 Million in Venture Financing 13
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 14
PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 16
Licensing Agreements 18
PhaseBio Pharma Enters into Licensing Agreement with MedImmune 18
Duke University Enters into Licensing Agreement with PhaseBio Pharma 19
Equity Offering 20
PhaseBio Pharma to Raise up to USD70 Million in Initial Public Offering of Shares 20
Debt Offering 21
PhaseBio Pharma to Raise USD8.1 Million in Second Tranche of Private Placement of Convertible Notes 21
PhaseBio Pharma Raises USD14.7 Million in Private Placement of Convertible Notes 23
PhaseBio Pharmaceuticals Inc – Key Competitors 25
PhaseBio Pharmaceuticals Inc – Key Employees 26
PhaseBio Pharmaceuticals Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Jul 19, 2018: PhaseBio appoints Caroline M. Loewy to board of directors 28
Mar 05, 2018: PhaseBio Announces Board Changes 29
Product News 30
02/27/2018: PhaseBio Awarded $2.8 Million NIH SBIR Grant to Support Clinical Development of PB1046 in Pulmonary Arterial Hypertension 30
Clinical Trials 31
Nov 01, 2017: PhaseBio Announces Dosing of First Patient in an Exploratory Clinical Study of PB1046 for the Treatment of Pulmonary Arterial Hypertension 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PhaseBio Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 11
PhaseBio Pharma Raises USD6.6 Million in Venture Financing 13
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 14
PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 16
PhaseBio Pharma Enters into Licensing Agreement with MedImmune 18
Duke University Enters into Licensing Agreement with PhaseBio Pharma 19
PhaseBio Pharma to Raise up to USD70 Million in Initial Public Offering of Shares 20
PhaseBio Pharma to Raise USD8.1 Million in Second Tranche of Private Placement of Convertible Notes 21
PhaseBio Pharma Raises USD14.7 Million in Private Placement of Convertible Notes 23
PhaseBio Pharmaceuticals Inc, Key Competitors 25
PhaseBio Pharmaceuticals Inc, Key Employees 26
PhaseBio Pharmaceuticals Inc, Other Locations 27

List of Figures
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PhaseBio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[PhaseBio Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kadant Inc. (KAI):企業の財務・戦略的SWOT分析
    Kadant Inc. (KAI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Newrest Group International S.A.S:企業の戦略・SWOT・財務情報
    Newrest Group International S.A.S - Strategy, SWOT and Corporate Finance Report Summary Newrest Group International S.A.S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Eldorado Gold Corporation:企業の戦略・SWOT・財務情報
    Eldorado Gold Corporation - Strategy, SWOT and Corporate Finance Report Summary Eldorado Gold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Soitec SA (SOI):企業の財務・戦略的SWOT分析
    Soitec SA (SOI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Chembio Diagnostic Inc (CEMI):医療機器:M&Aディール及び事業提携情報
    Summary Chembio Diagnostic Inc (Chembio) develops, manufactures, markets and licenses point-of-care diagnostic (POCs) tests for the detection of infectious diseases. The company offers products to prevent the spread of infectious diseases with solutions like Dual Path Platform (DPP). Its DPP technol …
  • Essar Steel Ltd:企業の戦略・SWOT・財務情報
    Essar Steel Ltd - Strategy, SWOT and Corporate Finance Report Summary Essar Steel Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Daxor Corp (DXR):企業の財務・戦略的SWOT分析
    Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Dialog Group Bhd (DIALOG):企業の財務・戦略的SWOT分析
    Dialog Group Bhd (DIALOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Youlchon Chemical Co Ltd:企業の戦略・SWOT・財務情報
    Youlchon Chemical Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Youlchon Chemical Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • LG Chem Ltd (051910):企業の財務・戦略的SWOT分析
    LG Chem Ltd (051910) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Confused.com Limited:企業の戦略・SWOT・財務情報
    Confused.com Limited - Strategy, SWOT and Corporate Finance Report Summary Confused.com Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Monsanto Co (MON):製薬・医療:M&Aディール及び事業提携情報
    Summary Monsanto Company (Monsanto) is an agricultural products manufacturing company. It develops and delivers agricultural products to support farmers all around the world. The company develops biotechnology traits that assist farmers in controlling insects and weeds. It also provides other seed c …
  • Posco Daewoo Corporation (047050)-石油・ガス分野:企業M&A・提携分析
    Summary Posco Daewoo Corporation (Posco Daewoo), formally known as Daewoo International Corporation, is an international trading and investment company. It is involved in international trade, resource development and project organizing businesses. The company’s operational activities include export …
  • Eurofarma Laboratorios SA-製薬・医療分野:企業M&A・提携分析
    Summary Eurofarma Laboratorios SA (Eurofarma), formerly Bill Farmaceutica is a pharmaceutical company that manufactures and markets prescription, generic and veterinary drugs. The company offers prescription products which include aerosol ointment, alprazolam, acebrophylline, altiva, ebastel, fluoru …
  • Inivata Ltd:企業の製品パイプライン分析
    Summary Inivata Ltd (Inivata) is a cancer genomics company that harnesses liquid biopsy platform to enhance personalized healthcare in oncology. The company’s product portfolio includes InVisionFirst – Lung, which offers advanced sequencing technology to detect copy number variants, single nucleotid …
  • LG Display Co Ltd:企業の戦略・SWOT・財務情報
    LG Display Co Ltd - Strategy, SWOT and Corporate Finance Report Summary LG Display Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Bata India Limited:戦略・SWOT・企業財務分析
    Bata India Limited - Strategy, SWOT and Corporate Finance Report Summary Bata India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • IREN SpA (IRE):企業の財務・戦略的SWOT分析
    IREN SpA (IRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Theratechnologies Inc (TH):企業の財務・戦略的SWOT分析
    Theratechnologies Inc (TH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • genedrive plc (GDR):企業の財務・戦略的SWOT分析
    genedrive plc (GDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆